Factor Xa Inhibitor Crystalline Forms
    3.
    发明申请
    Factor Xa Inhibitor Crystalline Forms 审中-公开
    因子Xa抑制剂结晶形式

    公开(公告)号:US20080194643A1

    公开(公告)日:2008-08-14

    申请号:US11909368

    申请日:2006-03-13

    CPC分类号: C07D401/12

    摘要: Disclosed are crystalline forms A, B and C of 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1(2H)-pyridinyl)phenyl]-4-methoxy-, (2R,4R)-(9Cl). These crystalline forms are characterized by their powder X-ray diffraction, solid-state NMR, as well as methods for the preparation and pharmaceutical compositions of the same which are useful for the treatment of acute, subacute, or chronic thrombotic disorders including treatment of venous thrombosis, arterial thrombosis, pulmonary embolism, myocardial infarction, cerebral infarction, restenosis, atherosclerosis, angina, primary and secondary deep vein thrombosis, thromboembolism associated with cardiovascular disease, including, but not limited to, acute coronary syndrome, atrial fibrillation, cardiac valve replacement and deep vein thrombosis. The crystalline forms of the present invention are also useful for the treatment of cancer, sepsis and diabetes.

    摘要翻译: 公开了1,2-吡咯烷二甲酰胺,N1-(4-氯苯基)-N2- [2-氟-4-(2-氧代-1(2H) - 吡啶基)苯基] -4- 甲氧基 - ,(2R,4R) - (9Cl)。 这些结晶形式的特征在于它们的粉末X射线衍射,固体NMR,以及其制备方法及其药物组合物,其可用于治疗急性,亚急性或慢性血栓形成疾病,包括静脉治疗 血栓形成,动脉血栓形成,肺栓塞,心肌梗塞,脑梗塞,再狭窄,动脉粥样硬化,心绞痛,原发性和继发性深静脉血栓形成,与心血管疾病相关的血栓栓塞,包括但不限于急性冠状动脉综合征,心房颤动,心脏瓣膜置换 和深静脉血栓形成。 本发明的结晶形式也可用于治疗癌症,败血症和糖尿病。